SCHEMBL3758759

SCHEMBL3758759

CN(C)C(=O)c1ccn[c]c1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.50
MEN1 O00255 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
NPC1 O15118 1/20 0.37
KEAP1 Q14145 1/20 0.36
KDM4E B2RXH2 3/20 0.35
GLA P06280 1/20 0.35
SLC40A1 Q9NP59 1/20 0.35
PKN1 Q16512 1/20 0.35
PKN2 Q16513 1/20 0.35
TP53 P04637 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
HIF1A Q16665 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ADRA1D P25100 1/20 0.34
ADRA1A P35348 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3769349 0.85 TRPM8 (0.47) KMT2AMEN1SMN1; SMN2ALDH1A1HPGD
SCHEMBL3759975 0.85 TRPM8 (0.37) KMT2AMEN1SMN1; SMN2RAB9AALDH1A1
SCHEMBL3763681 0.84 KMT2A (0.42) KMT2AMEN1SMN1; SMN2ALDH1A1HPGD
SCHEMBL3764668 0.84 HPGD (0.49) ALDH1A1HPGDKEAP1TP53MAPK1
SCHEMBL3761229 0.82 SMN1; SMN2 (0.40) KMT2ASMN1; SMN2RAB9AALDH1A1HPGD
SCHEMBL3759347 0.82 ALDH1A1 (0.41) SMN1; SMN2RAB9AALDH1A1HPGDNPC1
SCHEMBL3751948 0.79 SMN1; SMN2 (0.47) KMT2AMEN1SMN1; SMN2RAB9AALDH1A1
SCHEMBL3761415 0.79 BCAT2 (0.46) KMT2AMEN1RAB9AALDH1A1HPGD
SCHEMBL3769036 0.78 GAA (0.41) RAB9AALDH1A1HPGDNPC1KDM4E
SCHEMBL3761527 0.78 MEN1 (0.46) KMT2AMEN1SMN1; SMN2RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA KMT2A 2175/4885MEN1 2762/4885SMN1; SMN2 1864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.